Immediate hypersensitivity reaction to ixekizumab in a patient with psoriasis.

Ixekizumab is a humanized immunoglobulin G monoclonal antibody targeting the IL-17A, and labelled to treat moderate-to-severe plaque psoriasis. Similarly, we found an observation with positive IDT but negative SPT to ixekizumab and negative tests to polysorbate.5 The patient had immediate and delayed skin reaction at the injection site after a single injection of ixekizumab. Are injection site reactions in monoclonal antibody therapies caused by polysorbate excipient degradants?. [Extracted from the article]